Severe, refractory, non-malignant type I cryoglobulinemia treated with alemtuzumab.
A 41 year old female with type I cryoglobulinemia, refractory to methylprednisolone, rituximab, and cyclophosphamide complicated by a rising serum viscosity was treated with alemtuzumab. After a cumulative dose of 1,085 mg of alemtuzumab, her serum viscosity decreased to normal. Treatment toxicity was limited to fungal esophagitis responsive to topical therapy. This case demonstrates the potential use of alemtuzumab in the treatment of refractory cryoglobulinemia.